A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN027)

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN027)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Gefapixant (Primary)
  • Indications Cough
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Afferent Pharmaceuticals; Merck Sharp & Dohme
  • Most Recent Events

    • 02 Apr 2018 Planned primary completion date changed from 13 Nov 2019 to 20 Sep 2019.
    • 15 Mar 2018 Planned End Date changed from 5 Sep 2020 to 6 Jul 2020.
    • 15 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top